Belrose Pharma Acquires Enzon's Advanced Drug Formulation Technology and Associated Clinical Assets

Belrose Pharma has acquired Enzon's Advanced Drug Formulation Technology (Peglyation Linker Technology) and the associated product pipeline. Acquisition of this technology will enable Belrose Pharma to accelerate creation of improved biologic and small molecule therapies with better treatment outcomes for patients with life-threatening diseases such as breast cancer and pediatric neuroblastoma, and orphan drug diseases such as hereditary angioedema (HAE).